MRI for Salivary Gland Tumors
(PSGT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to enhance doctors' ability to distinguish between cancerous and non-cancerous tumors in the salivary glands using advanced MRI (Magnetic Resonance Imaging) scans. Researchers hope this will improve predictions of tumor behavior and lead to better treatment plans. The trial is open to individuals with a salivary gland lump at least the size of a small marble who have not yet received treatment for it. As an unphased trial, participants can contribute to groundbreaking research that may improve future diagnostic and treatment strategies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that MRI is safe for identifying salivary gland tumors?
Research shows that MRI (Magnetic Resonance Imaging) safely and comfortably examines salivary gland tumors. MRI uses magnets and radio waves to create images of the body's interior, avoiding radiation and enhancing safety.
Studies have demonstrated that MRI accurately distinguishes between benign (non-cancerous) and malignant (cancerous) tumors in the salivary glands. For instance, one study found that MRI was 90% accurate in determining whether a tumor in the parotid gland (a salivary gland near the ear) was benign or malignant. This finding indicates that MRI is both safe and effective for diagnosing these tumors.
Overall, MRI is a common tool in medicine because it is non-invasive and usually doesn't cause side effects. This makes it a safe option for patients considering participation in this trial.12345Why are researchers excited about this trial?
Researchers are excited about using MRI for salivary gland tumors because it offers a non-invasive way to examine these tumors with incredible detail. Unlike traditional methods, such as biopsies or CT scans, MRI doesn't require any cutting or exposure to radiation. This makes it safer for patients and can provide clearer images to help doctors better understand the tumor's size and location. Ultimately, MRIs could lead to more accurate diagnoses and personalized treatment plans.
What evidence suggests that MRI is effective for identifying salivary gland tumors?
Research has shown that MRI, which participants in this trial will undergo, excels at diagnosing salivary gland tumors. Studies indicate that MRI accurately distinguishes between non-cancerous and cancerous tumors in the parotid gland, a major salivary gland, 90% of the time. MRI provides more detailed images than other scans, making it the best choice for assessing tumor spread. This advanced imaging helps doctors create better treatment plans by clearly showing the tumor's size and location. While some new techniques are still in development, MRI remains a dependable tool for understanding salivary gland tumors.12367
Who Is on the Research Team?
Sanjeev Chawla
Principal Investigator
Professor
Are You a Good Fit for This Trial?
This clinical trial is for individuals with salivary gland lesions at least 1cm3 in size, who haven't had any treatment for these lesions before. It's not suitable for pregnant individuals, those with a history of cancer (other than salivary gland tumors), people with conditions that make MRI unsafe, kidney disease patients, or anyone who has received radiation therapy to the head and neck.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo advanced MRI techniques to distinguish between benign and malignant salivary gland tumors
Follow-up
Participants are monitored for differentiation of malignant from benign neoplasms and progression-free survival
What Are the Treatments Tested in This Trial?
Interventions
- MRI
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
Abramson Cancer Center of the University of Pennsylvania
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Lead Sponsor
McCabe Fund
Collaborator